Thomas Steyer’s Immunovant IMVT Stock Holding History

Thomas Steyer’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224M	Buy	5,805,000 +4,259,000	+275%	+$130M	1.03%	25
2026 Q1	$38.4M	Buy	1,546,000 +1,534,000	+12,783%	+$39.7M	0.2%	49
2025 Q4	$305K	Hold	12,000	–	–	﹤0.01%	109
2025 Q3	$193K	Hold	12,000	–	–	﹤0.01%	125
2025 Q2	$192K	Hold	12,000	–	–	﹤0.01%	122
2025 Q1	$205K	Hold	12,000	–	–	﹤0.01%	120
2024 Q4	$297K	Hold	12,000	–	–	﹤0.01%	115
2024 Q3	$342K	Hold	12,000	–	–	﹤0.01%	117
2024 Q2	$317K	Buy	+12,000	New	+$341K	﹤0.01%	117
2024 Q1	–	Sell	-341,000	Closed	-$14.4M	–	183
2023 Q4	$14.4M	Sell	341,000 -163,000	-32%	-$6M	0.07%	74
2023 Q3	$19.3M	Buy	+504,000	New	+$11.4M	0.09%	76

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Thomas Steyer's IMVT Position: Q2 2026 in Review

Thomas Steyer increased its Immunovant (IMVT) stake by 275% in Q2 2026, buying an estimated $130M and bringing the position to 5,805,000 shares worth $224M. The position accounts for 1.03% of the portfolio, ranked #25.

Thomas Steyer first reported a position in IMVT in Q3 2023 and has held it in 11 quarters since. 224 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Thomas Steyer held 5,805,000 shares of Immunovant worth $224M as of Q2 2026.
Thomas Steyer bought 4,259,000 Immunovant shares in Q2 2026, an estimated $130M.
Immunovant made up 1.03% of Thomas Steyer's portfolio in Q2 2026, its #25 holding.
Thomas Steyer first reported a position in Immunovant in Q3 2023 and has held it in 11 quarters since.
224 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.